Published in Am J Hum Genet on January 01, 1979
Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet (2006) 8.33
Genetic control of the eighth component of complement. J Clin Invest (1979) 1.03
Complement-human histocompatibility antigen haplotypes in C2 deficiency. J Clin Invest (1981) 0.89
Genetic polymorphism of human plasminogen. Am J Hum Genet (1980) 0.81
A restriction fragment of the C2 gene is a unique marker for C2 deficiency and the uncommon C2 allele C2*B (a marker for type 1 diabetes). J Clin Invest (1991) 0.75
Nomenclature for human complement component C2. WHO-IUIS Nomenclature Sub-Committee. Bull World Health Organ (1992) 0.75
Serotyping for homotransplantation. 18. Refinement of microdroplet lymphocyte cytotoxicity test. Transplantation (1968) 8.51
Genetic polymorphism in human glycine-rich beta-glycoprotein. J Exp Med (1972) 5.61
Evidence for linkage between HL-A histocompatibility genes and those involved in the synthesis of the second component of complement. J Exp Med (1974) 3.38
Inherited structural polymorphism in human C2: evidence for genetic linkage between C2 and Bf. J Exp Med (1976) 2.89
Inherited deficiency of the second component of complement. Rheumatic disease associations. J Clin Invest (1976) 2.38
Linkage of HL-A and GBG. Vox Sang (1974) 2.23
The role of the histocompatibility-2-linked Ss-Slp region in the control of mouse complement. Proc Natl Acad Sci U S A (1973) 2.12
Hereditary C2 deficiency: Genetic studies and association with the HL-A system. J Exp Med (1975) 1.75
Assignment of the major histocompatibility complex to a region of the short arm of human chromosome 6. Proc Natl Acad Sci U S A (1977) 1.62
Estimating distances from the centromere by means of benign ovarian teratomas in man. Ann Hum Genet (1976) 1.40
Very close linkage between HLA-B and Bf inferred from allelic association. Nature (1977) 1.30
Hereditary C2 deficiency: diagnosis and HLA gene complex associations. J Immunol (1976) 1.28
Allotypes of complement components in man. Transplant Rev (1976) 1.27
Properdin factor B and histocompatibility loci linked in the rhesus monkey. Nature (1975) 1.27
Structural heterogeneity of C2 Complement protein and its genetic variants in man: a new polymorphism of the HLA region. Proc Natl Acad Sci U S A (1977) 1.14
Assignment of the major histocompatibility complex to chromosome No. 6 in a family with a pericentric inversion. Hum Hered (1974) 1.13
The Bf locus in the HLA region of chromosome 6: linkage and association studies. Humangenetik (1975) 1.07
The chromosomal order of genes controlling the major histocompatibility complex, properdin factor B, and deficiency of the second component of complement. J Clin Invest (1976) 1.00
The localization of the Bf locus within the MHS region on chromosome no. 6. Tissue Antigens (1976) 0.90
Bf maps between the HLA--A and D loci. Tissue Antigens (1976) 0.89
Association between HLA and cutaneous necrotizing venulitis. Arthritis Rheum (1976) 0.87
On the HLA-B,D map distance. Tissue Antigens (1977) 0.79
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med (2000) 11.90
Immunological studies concerning the nephritis of systemic lupus erythematosus. J Exp Med (1967) 10.22
Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest (1966) 8.64
Measurement of serum DNA-binding activity in systemic lupus erythematosus. N Engl J Med (1969) 6.16
Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med (1968) 5.95
Genetic polymorphism in human glycine-rich beta-glycoprotein. J Exp Med (1972) 5.61
The enhancement of bacterial phagocytosis by serum. The role of complement components and two cofactors. J Exp Med (1969) 4.96
Alper CA, Rosen FS: Studies of the in vivo behavior of human C'3 in normal subjects and patients. J Clin Invest (1967) 4.45
Human C'3: evidence for the liver as the primary site of synthesis. Science (1969) 4.17
Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum (1989) 4.02
Inherited structural polymorphism of the fourth component of human complement. Proc Natl Acad Sci U S A (1980) 3.97
Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med (1980) 3.95
Uncertainty in xenotransplantation: individual benefit versus collective risk. Nat Med (1998) 3.54
Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res (2001) 3.48
Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. N Engl J Med (1982) 3.40
Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire. J Exp Med (1990) 3.38
Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg (1968) 3.34
The pathogenesis of arthritis associated with viral hepatitis. Complement-component studies. N Engl J Med (1971) 3.31
Genetic polymorphism of the third component of human complement (C'3). J Clin Invest (1968) 3.10
Homozygous deficiency of C3 in a patient with repeated infections. Lancet (1972) 3.04
Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection. J Clin Invest (1970) 2.92
Inherited structural polymorphism in human C2: evidence for genetic linkage between C2 and Bf. J Exp Med (1976) 2.89
Deficiency of C3 inactivator in man. J Immunol (1971) 2.86
Inactivator of the third component of complement as an inhibitor in the properdin pathway. Proc Natl Acad Sci U S A (1972) 2.84
Statement on the nomenclature of human C4 allotypes. Immunobiology (1983) 2.66
Activation of the properdin pathway of complement in patients with gram-negative of bacteremia. N Engl J Med (1975) 2.63
Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med (1992) 2.63
International system for human gene nomenclature (1979) ISGN (1979). Cytogenet Cell Genet (1979) 2.58
Isolation and properties of a glycine-rich beta-glycoprotein of human serum. Biochim Biophys Acta (1970) 2.55
The opsonic fragment of the third component of human complement (C3). J Exp Med (1975) 2.51
CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med (1995) 2.48
Inherited deficiency of the second component of complement. Rheumatic disease associations. J Clin Invest (1976) 2.38
A computer based intervention to reduce unnecessary serologic testing. J Rheumatol (1999) 2.37
Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis (2003) 2.33
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33
Serum-dependent phagocytosis of paraffin oil emulsified with bacterial lipopolysaccharide. J Exp Med (1973) 2.25
Extended HLA/complement allele haplotypes: evidence for T/t-like complex in man. Proc Natl Acad Sci U S A (1983) 2.23
Increased susceptibility to infection in a patient with type II essential hypercatabolism of C3. N Engl J Med (1973) 2.17
Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3). N Engl J Med (1970) 2.08
Cytomegalovirus infection after renal allotransplantation. JAMA (1967) 2.08
Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest (1996) 2.07
Alterations in immunoregulatory T cell subsets in active systemic lupus erythematosus. J Clin Invest (1980) 2.06
Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med (1984) 2.03
Alteration of the cytotoxic action of sensitized lymphocytes by cholinergic agents and activators of adenylate cyclase. Proc Natl Acad Sci U S A (1972) 2.01
Polymorphism of the human complement C4 and steroid 21-hydroxylase genes. Restriction fragment length polymorphisms revealing structural deletions, homoduplications, and size variants. J Clin Invest (1986) 2.00
Silicone breast implants and rheumatic disease. Clinical, immunologic, and epidemiologic studies. Arthritis Rheum (1994) 1.97
The modulating influence of cyclic nucleotides upon lymphocyte-mediated cytotoxicity. J Exp Med (1973) 1.92
Immunofixation electrophoresis: a technique for the study of protein polymorphism. Vox Sang (1969) 1.88
Activation of leukemia viruses by graft-versus-host and mixed lymphocyte reactions in vitro. Proc Natl Acad Sci U S A (1972) 1.85
Immune complexes, complement, and anti-DNA in exacerbations of systemic lupus erythematosus (SLE). Medicine (Baltimore) (1981) 1.83
Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. J Clin Invest (1971) 1.83
Identity and cytotoxic capacity of cells infiltrating renal allografts. N Engl J Med (1975) 1.82
Selective gamma-g globulin deficiencies in patients with recurrent pyogenic infections. N Engl J Med (1970) 1.80
The relationship of glycine-rich -glycoprotein to factor B in the properdin system and to the cobra factor-binding protein of huan serum. J Exp Med (1973) 1.80
Antibodies to ribonucleic acid in systemic lupus erythematosus. Proc Natl Acad Sci U S A (1969) 1.79
Complement in human disease. Annu Rev Med (1968) 1.79
Genetic polymorphism of human complement C4 and detection of heterozygotes. Nature (1979) 1.73
Renal tubular acidosis, glomerulonephritis and immunologic factors in Sjögren's syndrome. Arthritis Rheum (1968) 1.72
Serum complement component levels in human glomerulonephritis. Ann Intern Med (1971) 1.70
A method for increasing the sensitivity of radial-immunodiffusion assay. Lancet (1970) 1.70
Studies of hepatic synthesis in vivo of plasma proteins, including orosomucoid, transferrin, alpha 1-antitrypsin, C8, and factor B. Clin Immunol Immunopathol (1980) 1.69
Maternal-fetal relation. Absence of an immunologic blocking factor from the serum of women with chronic abortions. N Engl J Med (1976) 1.69
Lymphocyte surface immunoglobulins. Distribution and frequency in lymphoproliferative diseases. N Engl J Med (1973) 1.69
Type I diabetes mellitus in monozygotic twins: chronic progressive beta cell dysfunction. Ann Intern Med (1983) 1.68
Proteins phosphorylated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J Exp Med (1997) 1.66
Immunologic studies of juvenile rheumatoid arthritis. Arthritis Rheum (1972) 1.65
Study of four new kindreds with inherited thyroxine-binding globulin abnormalities. Possible mutations of a single gene locus. J Clin Invest (1972) 1.64
Automated quantitation of proteins in serum and other biologic fluids. Am J Clin Pathol (1973) 1.62
Heavy chain subclass of human anti-platelet antibodies. Clin Immunol Immunopathol (1973) 1.61
Extended major histocompatibility complex haplotypes in type I diabetes mellitus. J Clin Invest (1984) 1.58
Renal transplantation in the inbred rat. 3. A study of heterologous anti-thymocyte sera. J Exp Med (1967) 1.57
Inherited deficiency of the third component of human complement (C'3). J Clin Invest (1969) 1.56
Enzyme immunoassay for antibodies to native DNA. Specificity and quality of antibodies. Arthritis Rheum (1983) 1.56
Linkage between the gene (or genes) controlling synthesis of the fourth component of complement and the major histocompatibility complex. N Engl J Med (1977) 1.55
Enzymatic treatment transforms trypomastigotes of Trypanosoma cruzi into activators of alternative complement pathway and potentiates their uptake by macrophages. Proc Natl Acad Sci U S A (1981) 1.54
Genetic aspects of the complement system. Adv Immunol (1971) 1.52
Serum and synovial fluid IgG, IgA and IgM antigammaglobulins in rheumatoid arthritis. Arthritis Rheum (1972) 1.51
Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci U S A (1996) 1.51
Clinical laboratory test findings in patients with chronic fatigue syndrome. Arch Intern Med (1995) 1.50
The role of antibodies in the rejection and enhancement of organ allografts.?7318. Adv Immunol (1976) 1.48
Hypocomplementemia in rheumatoid arthritis. Arthritis Rheum (1971) 1.48
Complement components in synovial fluid: activation and fixation in seropositive rheumatoid arthritis. Ann N Y Acad Sci (1969) 1.46
Inheritable variable sizes of DNA stretches in the human MHC: conserved extended haplotypes and their fragments or blocks. Tissue Antigens (2003) 1.46
Avoidance of cyclosporine in renal transplantation: effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol (2000) 1.45
Beta-1C-globulin: metabolism in glomerulonephritis. Science (1966) 1.45
Genetic analysis of C4 deficiency. J Clin Invest (1981) 1.45
IgG subclasses--a review. Ann Allergy (1987) 1.45
Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement). Science (1976) 1.45
Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion. J Clin Invest (1978) 1.44
Very late activation antigens on rheumatoid synovial fluid T lymphocytes. Association with stages of T cell activation. J Clin Invest (1986) 1.43
Inheritance of human alpha-1-acid glycoprotein (orosomucoid) variants. J Clin Invest (1969) 1.43